{"nctId":"NCT00919893","briefTitle":"Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)","startDateStruct":{"date":"1999-12"},"conditions":["Chronic Prostatitis","Chronic Pelvic Pain Syndrome"],"count":139,"armGroups":[{"label":"Cernilton","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cernilton"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Cernilton","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* men between 18 and 65 years\n* symptoms of pelvic pain for at least 3 months during the 6 months before study entry\n* a score in the pain domain of the German validated version of the NIH chronic prostatitis symptom index (NIH-CPSI) of 7 or higher\n* leukocytes of 10 or more in post prostate massage urine\n\nExclusion Criteria:\n\n* urinary tract infection\n* acute bacterial or chronic bacterial prostatitis\n* history of urethritis with discharge 4 weeks prior to study entry\n* a history of epididymitis or sexually transmitted disease\n* residual urine volume of more than 50 mL due to bladder outlet obstruction\n* indication for or history of prostate surgery including prostate biopsy\n* treatment with phytotherapeutic agents\n* alpha-blocker agents or antimicrobial substances with prostatic penetration 4 weeks prior to study entry\n* treatment with agents influencing intraprostatic hormone metabolism 6 months prior to study entry","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Secondary Outcomes Were Symptomatic Improvement of the NIH-CPSI Total Score, the Micturition and Life Quality Domains of the NIH-CPSI Questionnaire, Decrease in the Number of Leukocytes in Urine.","description":"Decrease of score points. Decrease of leucocytes in urine.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI)","description":"Decrease in NIH-CPSI pain score. Best value: 0. Worst value: 21.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}